Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CTX-8371 |
| Synonyms | |
| Therapy Description |
CTX-8371 is a tetravalent bispecific antibody that targets CD274 (PD-L1) and PDCD1 (PD-1), potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (PMID: 38379869). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CTX-8371 | CTX 8371|CTX8371 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | CTX-8371 is a tetravalent bispecific antibody that targets CD274 (PD-L1) and PDCD1 (PD-1), potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (PMID: 38379869). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |